Research Paper Volume 13, Issue 8 pp 11043—11060
High expression of CD52 in adipocytes: a potential therapeutic target for obesity with type 2 diabetes
Figure 3. Anti-TGF-β/Smad3−/− mediated CD52 downregulation counteracts HFD-induced obesity and insulin resistance. (A, B) The expression levels of CD52 in preadipocytes from RD-fed or HFD-fed mice by Real-time RT-PCR and western blot analysis. (C) The expression levels of CD52 in WAT from RD-fed or HFD-fed KO mice and WT mice, and the expression levels of CD52 in WAT from HFD-fed KO mice and HFD-fed WT mice by microarray analysis. (D) The expression levels of CD52 in WAT from HFD-fed mice treated with anti-TGF-β antibody (1D11) and HFD-fed mice treated with control IgG by microarray analysis.